%0 Journal Article
%T Cell-based Vital Organs Specific Biomarkers Assessment Using Biofield Energy Based Novel Test Formulation - Cell-based Vital Organs Specific Biomarkers Assessment Using Biofield Energy Based Novel Test Formulation - Open Access Pub
%A Alice Branton
%A Dahryn Trivedi
%A Gopal Nayak
%A Janice Patricia Kinney
%A Mahendra Kumar Trivedi
%A Mayank Gangwar
%A Snehasis Jana
%J OAP | Home | Journal of Biotechnology and Biomedical Science | Open Access Pub
%D 2018
%X The aim of the present study was to determine the impact of Biofield Energy Treated test formulation using six differentcell-lines. The test formulation/item (TI) and cell media (Med) was divided into two parts; one part was untreated (UT) and other part received Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Janice Patricia Kinney, USA and labeled as Biofield Energy Treated (BT) test item (TI)/media. Based on cell viability assay, test formulation was found as safe at tested concentrations. Cytoprotective activity of test formulation showed a significant restoration of cell viability by 60.6% (10 ¦Ìg/mL), 67.5% (63.75 ¦Ìg/mL), and 117.5% (63.75 ¦Ìg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI, respectively compared to untreated in human cardiac fibroblasts cells (HCF) cells. Moreover, restoration of cell viability was improved by 64% and 127.3% in UT-Med + BT-TI and BT-Med + UT-TI, respectively at 1 ¦Ìg/mL compared to untreated in human liver cancer (HepG2) cells. Cellular restoration in A549 cells was improved by 314% and 112.3% at 1 ¦Ìg/mL in BT-Med + UT-TI and BT-Med + BT-TI, respectively than untreated. ALP activity in Ishikawa cells was significantly increased by 175.5%, 547.2%, and 220.8% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 0.1 ¦Ìg/mL as compared to untreated. Additionally, in MG-63 cells showed increased ALP activity by 76.9%, 78.4%, and 79% in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively at 50 ¦Ìg/mL compared to untreated. The percent cellular protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 60.6% (10 ¦Ìg/mL), 67.5% (63.75 ¦Ìg/mL), and 117.5% (63.75 ¦Ìg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI, respectively as compared to untreated. An improved HepG2 cells protection (represents decreased ALT activity) by 115.1% (1 ¦Ìg/mL), 42.5% (25.5 ¦Ìg/mL), and 60.8% (10 ¦Ìg/mL) in UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI, respectively as compared to untreated. Percentage cellular protection of A549 (lungs) cells (represents increased of SOD activity) was significantly increased by 191.1% and 81.4% at 0.1 ¦Ìg/mL in UT-Med + BT-TI and BT-Med + BT-TI, respectively as compared to untreated. Serotonin level was significantly increased by 31.8% (10 ¦Ìg/mL) and 56.9% (25.5 ¦Ìg/mL) in UT-Med + BT-TI and BT-Med + BT-TI, respectively compared to untreated in human neuroblastoma cells (SH-SY5Y). Relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 304.3% (0.01 ¦Ìg/mL), 128.4% (0.1 ¦Ìg/mL), and 240%
%U https://www.openaccesspub.org/jbbs/article/1128